{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T12:53:36Z","timestamp":1769518416099,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T00:00:00Z","timestamp":1533859200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Medical Excellence Award Funded by the Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1007\/s40261-018-0683-8","type":"journal-article","created":{"date-parts":[[2018,8,10]],"date-time":"2018-08-10T03:27:05Z","timestamp":1533871625000},"page":"909-925","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A Network Pharmacology-Based Analysis of Multi-Target, Multi-Pathway, Multi-Compound Treatment for Ovarian Serous Cystadenocarcinoma"],"prefix":"10.1007","volume":"38","author":[{"given":"Dan-dan","family":"Xiong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-qing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-quan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua-yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan-min","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-jing","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-wu","family":"Dang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4864-1451","authenticated-orcid":false,"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,8,10]]},"reference":[{"key":"683_CR1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359\u201386.","journal-title":"Int J Cancer"},{"key":"683_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"683_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.ygyno.2016.08.320","volume":"143","author":"A Kaldawy","year":"2016","unstructured":"Kaldawy A, Segev Y, Lavie O, Auslender R, Sopik V, Narod SA. Low-grade serous ovarian cancer: a review. Gynecol Oncol. 2016;143:433\u20138.","journal-title":"Gynecol Oncol"},{"key":"683_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/1756-8722-5-8","volume":"5","author":"J Li","year":"2012","unstructured":"Li J, Fadare O, Xiang L, Kong B, Zheng W. Ovarian serous carcinoma: recent concepts on its origin and carcinogenesis. J Hematol Oncol. 2012;5:8.","journal-title":"J Hematol Oncol."},{"key":"683_CR5","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1158\/1055-9965.EPI-16-0858","volume":"26","author":"LA Torre","year":"2017","unstructured":"Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. Cancer Epidemiol Biomark Prev. 2017;26:444\u201357.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"683_CR6","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1158\/1078-0432.CCR-16-1647","volume":"23","author":"A Bachmayr-Heyda","year":"2017","unstructured":"Bachmayr-Heyda A, Aust S, Auer K, Meier SM, Schmetterer KG, Dekan S, et al. Integrative systemic and local metabolomics with impact on survival in high-grade serous ovarian cancer. Clin Cancer Res. 2017;23:2081\u201392.","journal-title":"Clin Cancer Res"},{"key":"683_CR7","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RC Jr, Beral V, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668\u201379.","journal-title":"Nat Rev Cancer"},{"key":"683_CR8","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384:1376\u201388.","journal-title":"Lancet"},{"key":"683_CR9","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","volume":"4","author":"AL Hopkins","year":"2008","unstructured":"Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008;4:682\u201390.","journal-title":"Nat Chem Biol"},{"key":"683_CR10","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1039\/C5NP00005J","volume":"32","author":"M Kibble","year":"2015","unstructured":"Kibble M, Saarinen N, Tang J, Wennerberg K, Makela S, Aittokallio T. Network pharmacology applications to map the unexplored target space and therapeutic potential of natural products. Nat Prod Rep. 2015;32:1249\u201366.","journal-title":"Nat Prod Rep"},{"key":"683_CR11","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3724\/SP.J.1009.2013.00110","volume":"11","author":"S Li","year":"2013","unstructured":"Li S, Zhang B. Traditional Chinese medicine network pharmacology: theory, methodology and application. Chin J Nat Med. 2013;11:110\u201320.","journal-title":"Chin J Nat Med"},{"key":"683_CR12","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/COPD.S121079","volume":"12","author":"G Yu","year":"2017","unstructured":"Yu G, Zhang Y, Ren W, Dong L, Li J, Geng Y, et al. Network pharmacology-based identification of key pharmacological pathways of Yin-Huang-Qing-Fei capsule acting on chronic bronchitis. Int J Chron Obstruct Pulmon Dis. 2017;12:85\u201394.","journal-title":"Int J Chron Obstruct Pulmon Dis."},{"key":"683_CR13","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1038\/aps.2016.53","volume":"37","author":"Q Qi","year":"2016","unstructured":"Qi Q, Li R, Li HY, Cao YB, Bai M, Fan XJ, et al. Identification of the anti-tumor activity and mechanisms of nuciferine through a network pharmacology approach. Acta Pharmacol Sin. 2016;37:963\u201372.","journal-title":"Acta Pharmacol Sin"},{"key":"683_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.2174\/1570163811310020002","volume":"10","author":"AS Azmi","year":"2013","unstructured":"Azmi AS. Adopting network pharmacology for cancer drug discovery. Curr Drug Discov Technol. 2013;10:95\u2013105.","journal-title":"Curr Drug Discov Technol"},{"key":"683_CR15","doi-asserted-by":"publisher","first-page":"W98","DOI":"10.1093\/nar\/gkx247","volume":"45","author":"Z Tang","year":"2017","unstructured":"Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98\u2013102.","journal-title":"Nucleic Acids Res"},{"key":"683_CR16","doi-asserted-by":"publisher","first-page":"D833","DOI":"10.1093\/nar\/gkw943","volume":"45","author":"J Pinero","year":"2017","unstructured":"Pinero J, Bravo A, Queralt-Rosinach N, Gutierrez-Sacristan A, Deu-Pons J, Centeno E, et al. DisGeNET: a comprehensive platform integrating information on human disease-associated genes and variants. Nucleic Acids Res. 2017;45:D833\u20139.","journal-title":"Nucleic Acids Res"},{"key":"683_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1089\/omi.2011.0118","volume":"16","author":"G Yu","year":"2012","unstructured":"Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012;16:284\u20137.","journal-title":"OMICS"},{"key":"683_CR18","first-page":"146","volume":"3","author":"Guanming Wu","year":"2014","unstructured":"Wu G, Dawson E, Duong A, Haw R, Stein L. ReactomeFIViz: a Cytoscape app for pathway and network-based data analysis. F1000Res. 2014;3:146.","journal-title":"F1000Research"},{"key":"683_CR19","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/bib\/bbx023","volume":"18","author":"A Musa","year":"2017","unstructured":"Musa A, Ghoraie LS, Zhang SD, Glazko G, Yli-Harja O, Dehmer M, et al. A review of connectivity map and computational approaches in pharmacogenomics. Brief Bioinform. 2017;18:903.","journal-title":"Brief Bioinform"},{"key":"683_CR20","doi-asserted-by":"publisher","first-page":"D380","DOI":"10.1093\/nar\/gkv1277","volume":"44","author":"D Szklarczyk","year":"2016","unstructured":"Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2016;44:D380\u20134.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"683_CR21","doi-asserted-by":"publisher","first-page":"8.13.1-8.13.24","DOI":"10.1002\/0471250953.bi0813s47","volume":"47","author":"Gang Su","year":"2014","unstructured":"Su G, Morris JH, Demchak B, Bader GD. Biological network exploration with Cytoscape 3. Curr Protoc Bioinform. 2014;47:8.13.1\u201324.","journal-title":"Current Protocols in Bioinformatics"},{"key":"683_CR22","doi-asserted-by":"publisher","first-page":"D1202","DOI":"10.1093\/nar\/gkv951","volume":"44","author":"S Kim","year":"2016","unstructured":"Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, et al. PubChem substance and compound databases. Nucleic Acids Res. 2016;44:D1202\u201313.","journal-title":"Nucleic Acids Res"},{"key":"683_CR23","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3389\/fphys.2018.00151","volume":"9","author":"G Anda-Jauregui de","year":"2018","unstructured":"de Anda-Jauregui G, Guo K, McGregor BA, Hur J. Exploration of the anti-inflammatory drug space through network pharmacology: applications for drug eepurposing. Front Physiol. 2018;9:151.","journal-title":"Front Physiol."},{"key":"683_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fphar.2018.00187","volume":"9","author":"H Cao","year":"2018","unstructured":"Cao H, Li S, Xie R, Xu N, Qian Y, Chen H, et al. Exploring the mechanism of dangguiliuhuang decoction against hepatic fibrosis by network pharmacology and experimental validation. Front Pharmacol. 2018;9:187.","journal-title":"Front Pharmacol."},{"key":"683_CR25","doi-asserted-by":"crossref","first-page":"2960372","DOI":"10.1155\/2016\/2960372","volume":"2016","author":"H Liu","year":"2016","unstructured":"Liu H, Zeng L, Yang K, Zhang G. A network pharmacology approach to explore the pharmacological mechanism of xiaoyao powder on anovulatory infertility. Evid Based Compl Alternat Med. 2016;2016:2960372.","journal-title":"Evid Based Compl Alternat Med."},{"key":"683_CR26","doi-asserted-by":"publisher","first-page":"2441","DOI":"10.1039\/C4MB00287C","volume":"10","author":"J Du","year":"2014","unstructured":"Du J, Yuan Z, Ma Z, Song J, Xie X, Chen Y. KEGG-PATH: Kyoto Encyclopedia of Genes and Genomes-based pathway analysis using a path analysis model. Mol BioSyst. 2014;10:2441\u20137.","journal-title":"Mol BioSyst"},{"key":"683_CR27","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1001\/archgenpsychiatry.2011.1535","volume":"69","author":"CP Fagundes","year":"2012","unstructured":"Fagundes CP, Glaser R, Johnson SL, Andridge RR, Yang EV, Di Gregorio MP, et al. Basal cell carcinoma: stressful life events and the tumor environment. Arch Gen Psychiatry. 2012;69:618\u201326.","journal-title":"Arch Gen Psychiatry"},{"key":"683_CR28","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00423-011-0783-x","volume":"397","author":"T Flecken","year":"2012","unstructured":"Flecken T, Spangenberg HC, Thimme R. Immunobiology of hepatocellular carcinoma. Langenbecks Arch Surg. 2012;397:673\u201380.","journal-title":"Langenbecks Arch Surg."},{"key":"683_CR29","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1055\/s-0034-1394138","volume":"3","author":"MF Sprinzl","year":"2014","unstructured":"Sprinzl MF, Galle PR. Immune control in hepatocellular carcinoma development and progression: role of stromal cells. Semin Liver Dis. 2014;3:376\u201388.","journal-title":"Semin Liver Dis"},{"key":"683_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S0022-510X(02)00256-3","volume":"203\u2013204","author":"R Kalaria","year":"2002","unstructured":"Kalaria R. Similarities between Alzheimer\u2019s disease and vascular dementia. J Neurol Sci. 2002;203\u2013204:29\u201334.","journal-title":"J Neurol Sci"},{"key":"683_CR31","doi-asserted-by":"publisher","first-page":"8685","DOI":"10.1073\/pnas.0701361104","volume":"104","author":"KI Goh","year":"2007","unstructured":"Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. The human disease network. Proc Natl Acad Sci USA. 2007;104:8685\u201390.","journal-title":"Proc Natl Acad Sci USA."},{"key":"683_CR32","doi-asserted-by":"publisher","first-page":"e6536","DOI":"10.1371\/journal.pone.0006536","volume":"4","author":"G Hu","year":"2009","unstructured":"Hu G, Agarwal P. Human disease-drug network based on genomic expression profiles. PLoS One. 2009;4:e6536.","journal-title":"PLoS One"},{"key":"683_CR33","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.drudis.2012.07.017","volume":"1","author":"XA Qu","year":"2012","unstructured":"Qu XA, Rajpal DK. Applications of connectivity map in drug discovery and development. Drug Discov Today. 2012;1:1289\u201398.","journal-title":"Drug Discov Today."},{"issue":"1437\u201352","key":"683_CR34","first-page":"e17","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, et al. A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171(1437\u201352):e17.","journal-title":"Cell"},{"key":"683_CR35","doi-asserted-by":"publisher","first-page":"E3725","DOI":"10.1073\/pnas.1520289113","volume":"113","author":"B Malcomson","year":"2016","unstructured":"Malcomson B, Wilson H, Veglia E, Thillaiyampalam G, Barsden R, Donegan S, et al. Connectivity mapping (ssCMap) to predict A20-inducing drugs and their antiinflammatory action in cystic fibrosis. Proc Natl Acad Sci USA. 2016;113:E3725\u201334.","journal-title":"Proc Natl Acad Sci USA."},{"key":"683_CR36","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1038\/leu.2017.317","volume":"32","author":"V Walf-Vorderwulbecke","year":"2018","unstructured":"Walf-Vorderwulbecke V, Pearce K, Brooks T, Hubank M, van den Heuvel-Eibrink MM, Zwaan CM, et al. Targeting acute myeloid leukemia by drug-induced c-MYB degradation. Leukemia. 2018;32:882\u20139.","journal-title":"Leukemia"},{"key":"683_CR37","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.molonc.2015.01.002","volume":"9","author":"W Chien","year":"2015","unstructured":"Chien W, Sun QY, Lee KL, Ding LW, Wuensche P, Torres-Fernandez LA, et al. Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. Mol Oncol. 2015;9:889\u2013905.","journal-title":"Mol Oncol."},{"key":"683_CR38","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1016\/j.nut.2009.03.009","volume":"25","author":"M Sengottuvelan","year":"2009","unstructured":"Sengottuvelan M, Deeptha K, Nalini N. Influence of dietary resveratrol on early and late molecular markers of 1,2-dimethylhydrazine-induced colon carcinogenesis. Nutrition. 2009;25:1169\u201376.","journal-title":"Nutrition."},{"key":"683_CR39","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/cncr.29793","volume":"122","author":"L Tan","year":"2016","unstructured":"Tan L, Wang W, He G, Kuick RD, Gossner G, Kueck AS, et al. Resveratrol inhibits ovarian tumor growth in an in vivo mouse model. Cancer. 2016;122:722\u20139.","journal-title":"Cancer"},{"key":"683_CR40","doi-asserted-by":"publisher","first-page":"32627","DOI":"10.1038\/srep32627","volume":"6","author":"H Piotrowska-Kempisty","year":"2016","unstructured":"Piotrowska-Kempisty H, Rucinski M, Borys S, Kucinska M, Kaczmarek M, Zawierucha P, et al. 3\u2032-hydroxy-3,4,5,4\u2032-tetramethoxystilbene, the metabolite of resveratrol analogue DMU-212, inhibits ovarian cancer cell growth in vitro and in a mice xenograft model. Sci Rep. 2016;6:32627.","journal-title":"Sci Rep."},{"key":"683_CR41","doi-asserted-by":"publisher","first-page":"R209","DOI":"10.1530\/ERC-13-0171","volume":"21","author":"LG Carter","year":"2014","unstructured":"Carter LG, D\u2019Orazio JA, Pearson KJ. Resveratrol and cancer: focus on in vivo evidence. Endocr Relat Cancer. 2014;21:R209\u201325.","journal-title":"Endocr Relat Cancer"},{"key":"683_CR42","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1111\/bjh.12154","volume":"160","author":"R Popat","year":"2013","unstructured":"Popat R, Plesner T, Davies F, Cook G, Cook M, Elliott P, et al. A phase 2 study of SRT501 (resveratrol) with bortezomib for patients with relapsed and or refractory multiple myeloma. Br J Haematol. 2013;160:714\u20137.","journal-title":"Br J Haematol"},{"key":"683_CR43","doi-asserted-by":"publisher","first-page":"e25192","DOI":"10.1371\/journal.pone.0025192","volume":"6","author":"E Jong de","year":"2011","unstructured":"de Jong E, Winkel P, Poelstra K, Prakash J. Anticancer effects of 15d-prostaglandin-J2 in wild-type and doxorubicin-resistant ovarian cancer cells: novel actions on SIRT1 and HDAC. PLoS One. 2011;6:e25192.","journal-title":"PLoS One"},{"key":"683_CR44","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.3892\/or.2013.2959","volume":"31","author":"H Nagai","year":"2014","unstructured":"Nagai H, Fujioka-Kobayashi M, Ohe G, Hara K, Takamaru N, Uchida D, et al. Antitumour effect of valproic acid against salivary gland cancer in vitro and in vivo. Oncol Rep. 2014;31:1453\u20138.","journal-title":"Oncol Rep"},{"key":"683_CR45","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.3892\/ijo.2017.4103","volume":"51","author":"G Mattheolabakis","year":"2017","unstructured":"Mattheolabakis G, Wang R, Rigas B, Mackenzie GG. Phospho-valproic acid inhibits pancreatic cancer growth in mice: enhanced efficacy by its formulation in poly-(l)-lactic acid-poly(ethylene glycol) nanoparticles. Int J Oncol. 2017;51:1035\u201344.","journal-title":"Int J Oncol"},{"key":"683_CR46","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1517\/13543784.2013.853037","volume":"22","author":"L Cincarova","year":"2013","unstructured":"Cincarova L, Zdrahal Z, Fajkus J. New perspectives of valproic acid in clinical practice. Expert Opin Investig Drugs. 2013;22:1535\u201347.","journal-title":"Expert Opin Investig Drugs"},{"key":"683_CR47","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1007\/s10637-013-0003-3","volume":"31","author":"GS Falchook","year":"2013","unstructured":"Falchook GS, Fu S, Naing A, Hong DS, Hu W, Moulder S, et al. Methylation and histone deacetylase inhibition in combination with platinum treatment in patients with advanced malignancies. Invest New Drugs. 2013;31:1192\u2013200.","journal-title":"Invest New Drugs"},{"key":"683_CR48","first-page":"879746","volume":"2013","author":"JH Jung","year":"2013","unstructured":"Jung JH, Sohn EJ, Shin EA, Lee D, Kim B, Jung DB, et al. Melatonin suppresses the expression of 45S preribosomal RNA and upstream binding factor and enhances the antitumor activity of puromycin in MDA-MB-231 breast cancer cells. Evid Based Complement Alternat Med. 2013;2013:879746.","journal-title":"Evid Based Complement Alternat Med."},{"key":"683_CR49","doi-asserted-by":"publisher","first-page":"e1934","DOI":"10.1038\/cddis.2015.292","volume":"6","author":"SV Singh","year":"2015","unstructured":"Singh SV, Ajay AK, Mohammad N, Malvi P, Chaube B, Meena AS, et al. Proteasomal inhibition sensitizes cervical cancer cells to mitomycin C-induced bystander effect: the role of tumor microenvironment. Cell Death Dis. 2015;6:e1934.","journal-title":"Cell Death Dis."},{"key":"683_CR50","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1158\/0008-5472.CAN-06-3793","volume":"67","author":"W Li","year":"2007","unstructured":"Li W, Zhang X, Olumi AF. MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos\/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res. 2007;67:2247\u201355.","journal-title":"Cancer Res"},{"key":"683_CR51","doi-asserted-by":"crossref","first-page":"56508","DOI":"10.18632\/oncotarget.10643","volume":"7","author":"H Lu","year":"2016","unstructured":"Lu H, Yang XF, Tian XQ, Tang SL, Li LQ, Zhao S, et al. The in vitro and vivo anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells. Oncotarget. 2016;7:56508\u201325.","journal-title":"Oncotarget."},{"key":"683_CR52","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1097\/IGC.0000000000000703","volume":"26","author":"N Guo","year":"2016","unstructured":"Guo N, Peng Z, Zhang J. Proteasome inhibitor MG132 enhances sensitivity to cisplatin on ovarian carcinoma cells in vitro and in vivo. Int J Gynecol Cancer. 2016;26:839\u201344.","journal-title":"Int J Gynecol Cancer."},{"issue":"4","key":"683_CR53","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/med.21389","volume":"36","author":"Paola Vitale","year":"2016","unstructured":"Vitale P, Panella A, Scilimati A, Perrone MG. COX-1 inhibitors: beyond structure toward therapy. Med Res Rev. 2016;36:641\u201371.","journal-title":"Medicinal Research Reviews"},{"key":"683_CR54","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3109\/07357907.2012.666690","volume":"30","author":"J Lubig","year":"2012","unstructured":"Lubig J, Lattrich C, Springwald A, Haring J, Schuler S, Ortmann O, et al. Effects of a combined treatment with GPR30 agonist G-1 and herceptin on growth and gene expression of human breast cancer cell lines. Cancer Invest. 2012;30:372\u20139.","journal-title":"Cancer Invest"},{"key":"683_CR55","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2174\/1568009614666140320111306","volume":"14","author":"MD Hjortso","year":"2014","unstructured":"Hjortso MD, Andersen MH. The expression, function and targeting of haem oxygenase-1 in cancer. Curr Cancer Drug Targets. 2014;14:337\u201347.","journal-title":"Curr Cancer Drug Targets"},{"key":"683_CR56","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s10616-017-0154-8","volume":"70","author":"M Yildiz-Ozer","year":"2018","unstructured":"Yildiz-Ozer M, Oztopcu-Vatan P, Kus G. The investigation of ceranib-2 on apoptosis and drug interaction with carboplatin in human non small cell lung cancer cells in vitro. Cytotechnology. 2018;70:387\u201396.","journal-title":"Cytotechnology"},{"key":"683_CR57","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1016\/j.ygyno.2012.11.029","volume":"128","author":"C Ivan","year":"2013","unstructured":"Ivan C, Hu W, Bottsford-Miller J, Zand B, Dalton HJ, Liu T, et al. Epigenetic analysis of the Notch superfamily in high-grade serous ovarian cancer. Gynecol Oncol. 2013;128:506\u201311.","journal-title":"Gynecol Oncol"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-018-0683-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0683-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-018-0683-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T08:28:17Z","timestamp":1751790497000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-018-0683-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,10]]},"references-count":57,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["683"],"URL":"https:\/\/doi.org\/10.1007\/s40261-018-0683-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,10]]},"assertion":[{"value":"10 August 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by a Medical Excellence Award funded by a Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Dan-dan Xiong, Yue Qin, Wen-qing Xu, Rong-quan He, Hua-yu Wu, Dan-min Wei, Jing-jing Zeng, Yi-wu Dang, and Gang Chen have no conflicts of interest directly relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}